Prescribing Trends of Biologic Disease-Modifying Anti-rheumatic Drugs Using a Claims Database from 6 Million People in Japan
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-021-01082-x
Abstract: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are used either when conventional synthetic DMARDs are ineffective or when disease activity is high and with poor prognostic factors, based on various clinical guidelines. The purpose of this study… read more here.
Keywords: anti rheumatic; claims database; disease modifying; biologic disease ... See more keywords
E075 Predictive factors for successful biologic disease-modifying anti-rheumatic drugs dose tapering in rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.324
Abstract: Use of biologic disease-modifying anti-rheumatic drugs (bDMARDs) have revolutionised the management of rheumatoid arthritis (RA). However, their use is not without side effects including infection and malignancy risk. Recent EULAR and ACR guidelines support consideration… read more here.
Keywords: dose tapering; anti rheumatic; biologic disease; rheumatoid ... See more keywords
Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children
Sign Up to like & getrecommendations! Published in 2022 at "Current Opinion in Rheumatology"
DOI: 10.1097/bor.0000000000000889
Abstract: Purpose of review Multisystem inflammatory syndrome in children (MIS-C) is a postinfectious complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primarily affecting children. MIS-C shares features with Kawasaki disease (KD) and cytokine storm… read more here.
Keywords: disease; biologic disease; inflammatory syndrome; syndrome children ... See more keywords
Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti‐rheumatic agents for the treatment of psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.12685
Abstract: In Singapore, patients with psoriatic arthritis (PsA) constitute a significant disease burden. There is good evidence for the efficacy of anti‐tumor necrosis factor (anti‐TNF) in PsA; however cost remains a limiting factor. Non‐biologic disease modifying… read more here.
Keywords: modifying anti; psoriatic arthritis; anti rheumatic; disease modifying ... See more keywords
Consensus development on eligibility of government subsidisation of biologic disease modifying anti‐rheumatic agents for treatment of ankylosing spondylitis: The Singapore experience
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.12707
Abstract: The beneficial effects of biologic disease‐modifying anti‐rheumatic drugs (bDMARDs), such as tumour necrosis factor inhibitors (anti‐TNF) in active ankylosing spondylitis (AS) are well established. The significant costs on patients in the absence of financial subsidization… read more here.
Keywords: modifying anti; anti rheumatic; ankylosing spondylitis; consensus development ... See more keywords
Analysis of formulary coverage and cost of biologic disease modifying anti‐rheumatic drugs in Medicare Part D
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmaceutical Health Services Research"
DOI: 10.1111/jphs.12231
Abstract: Biologic disease modifying anti‐rheumatic drugs (DMARDs) are effective for the treatment of rheumatoid arthritis but also expensive. Medicare covers an important part of the cost of biologic DMARDs in the United States; however, studies examining… read more here.
Keywords: part; coverage cost; medicare part; biologic disease ... See more keywords
SAT0269 The effect of biologic disease-modifying antirheumatic drugs in targeting disease remission in axial spondyloarthritis (AXSPA): a systematic literature review
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.4979
Abstract: Background The treat-to-target concept is currently recommended in axSpA management and remission is the main objective of treatment. Although consensual definitions of remission are lacking, most authors assume remission as a state of inactive disease… read more here.
Keywords: axspa; remission; disease; biologic disease ... See more keywords
Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s375890
Abstract: Purpose Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are highly effective and safe against juvenile idiopathic arthritis (JIA), which is classified into systemic JIA (sJIA) and the other JIA categories (non-sJIA) according to differences in clinical symptoms… read more here.
Keywords: claims database; biologic disease; jia; modifying anti ... See more keywords
Cardiovascular effects of biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Sign Up to like & getrecommendations! Published in 2020 at "Current vascular pharmacology"
DOI: 10.2174/1570161118666200214115532
Abstract: The risk of cardiovascular (CV) disease is increased among patients with systemic autoimmune rheumatic diseases and remains an underserved area of medical need. Although traditional risk factors for CV disease, such as hypertension, smoking, dyslipidemia… read more here.
Keywords: risk; effects biologic; disease modifying; disease ... See more keywords